The present invention a Bifidobacterium longum CBT BG7 Bifidobacterium, which has an excellent growth promoting effect and was internationally deposited with the Korean Collection for Type Culture (KCTC) of the Korea Research Institute of Bioscience and Biotechnology under accession number KCTC 12200BP. The strain of the present invention has a beneficial effect of promoting growth by promoting the digestion of human milk oligosaccharides to enhance immunity together with physical strength.

An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

An oral composition comprising at least one probiotic bacteria selected from the genera: Lactobacillus, Bifidobacterium, and Bacillus, and ferric pyrophosphate.

The invention pertains to the use of a probiotic and a beta-lactoglobulin-derived peptide in the manufacture of a product for use in inducing oral tolerance, and/or treatment, prevention or reducing the risk of allergy in a subject, in particular cow's milk protein allergy.

The present invention is a yogurt product that may be consumed by dogs and other mammalian pets. The yogurt product is in an unflavored form comprising as essential constituents: (A) 0% to 88% by weight water; (B) 0.2% to 25% by weight of a no-fat protein component selected from the group consisting of skim milk and cultured skim milk; (C1) 0.001% to 6% by weight sugar component comprising: (C1) 0.001% to 6% polydextrose and (C2) 0.001% to 6% Glycoses and Galactoses; (D) 2% to 8% by weight milk derived solids; (E) 0.2% to 2.5% by weight stabilizers and emulsifiers; and (F) at least one probiotic microorganism. The yogurt product may be refrigerated and served as a mousse, frozen dessert, or as a fermented yogurt drink similar to Ayran or Kefir. A method for producing the yogurt product is also disclosed herein.

A process of producing beverage includes washing and drying cactus fruit and pitaya; juicing the cactus fruit to obtain juice of the cactus fruit and juicing the pitaya to obtain juice of the pitaya respectively; filtering the juice of the cactus fruit and the juice of the pitaya respectively; mixing the filtered juice of the cactus fruit and the filtered juice of the pitaya with water to obtain a solution; pouring yeast and gram-positive bacteria in the solution wherein the yeast is saccharomyces boulardii and the gram-positive bacteria includes lactobacillus acidophilus and bifidobacterium longum; and fermenting the solution until beverage is produced wherein fermentation temperature is between 26 C. and 35 C. and fermentation time lasts for 3 to 10 days.

A sweetener composition comprising xylose, a sugar alcohol and brown seaweed extract in solid form, preferably powdered or crystalline form. The sugar alcohol is preferably an erythritol and the brown seaweed extract is preferably obtained from Laminaria japonica. The sweetener composition can further comprise one or a combination of additional vitamins, minerals, probiotic cultures, and other plant-based extracts.

The present invention relates to the use of Lactobacillus rhamnosus in combination with Bifidobacterium longum to manufacture a formulation to increase male fertility in a subject. In particular, said strains are the strains Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347. Additionally, the formulation comprising the said strains Lactobacillus rhamnosus CECT 8361 and Bifidobacterium longum CECT 7347 is also described.

The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.

A method for inhibiting xanthine oxidase and for reducing uric acid levels using a pharmaceutical composition or a food product obtained by culturing Gluconacetobacter hansenii or Acetobacter pasteurianus in a medium. Also disclosed is a pharmaceutical composition and a food product that each include a metabolite of Gluconacetobacter hansenii or Acetobacter pasteurianus for reducing uric acid levels in a subject and methods for producing the pharmaceutical composition and the food product.